a Mental Health Group, University of Southampton, Southampton, UK
b E. Lilly Regional Operations, Vienna, Austria
c Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
*Corresponding author. Present address. Department of Psychiatry, Royal South Hants Hospital, Brittons Terrace, Southampton, S014 OYD, UK. Tel.: +44 2380 79 6581.
Second generation antipsychotic agents are increasingly used in the management of acute mania. A systematic review of the efficacy and safety of these agents, as both monotherapy and in combination with mood stabilisers, was performed to establish the evidence for their use. Randomised controlled trials (RCTs) were critically appraised in more detail than studies that presented lower levels of evidence such as case reports, case series and open label follow up studies. We found 11 RCTs reporting on patients treated with second generation antipsychotics for acute bipolar mania, of which three included randomisation between the second generation antipsychotic and placebo, and eight between a mood stabiliser combined with either the second generation antipsychotic or placebo. Data from non-randomised trials is also presented.
Keywords : Mania, Bipolar disorder, Second generation, Antipsychotic, Efficacy, Safety
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925. As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted. Personal information regarding our website's visitors, including their identity, is confidential. The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
You can move this window by clicking on the headline